Fig. 2.

Clinical course since the third hospitalization. Inflammation reaction reduced after 5-ASA treatment. Due to drug-induced liver injury, 5-ASA had to be discontinued and the colitis flared up. Ustekinumab improved colitis and did not induce rejection in grafted heart.

WBC, white blood cell; CRP, C-reactive protein; TCR, tacrolimus; MMF, mycophenolate mofetil; CDAI, Crohn's Disease Activity Index; 5-ASA, 5-aminosalicylic acid; IV, intravenous injection; SC, subcutaneous injection; m, month.